ATE275962T1 - Behandlung von prostatakrebs mit lhrh- antagonisten - Google Patents

Behandlung von prostatakrebs mit lhrh- antagonisten

Info

Publication number: ATE275962T1
Authority: AT; Austria
Prior art keywords: lhrh; methods; therapy; lhrh antagonist; combination
Prior art date: 1995-12-15

Application number

AT96942812T

Other languages

English (en)

Inventor

Marc B Garnick

Christopher J Molineaux

Malcolm L Gefter

Original Assignee

Praecis Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-12-15

Filing date

1996-11-25

Publication date

2004-10-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24290700&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE275962(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1996-11-25 Application filed by Praecis Pharm Inc filed Critical Praecis Pharm Inc

2004-10-15 Application granted granted Critical

2004-10-15 Publication of ATE275962T1 publication Critical patent/ATE275962T1/de

Links

229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 title abstract 7
206010060862 Prostate cancer Diseases 0.000 title 1
208000000236 Prostatic Neoplasms Diseases 0.000 title 1
239000002474 gonadorelin antagonist Substances 0.000 abstract 6
238000000034 method Methods 0.000 abstract 6
238000002560 therapeutic procedure Methods 0.000 abstract 4
101000904173 Homo sapiens Progonadoliberin-1 Proteins 0.000 abstract 3
102100024028 Progonadoliberin-1 Human genes 0.000 abstract 3
101000996723 Sus scrofa Gonadotropin-releasing hormone receptor Proteins 0.000 abstract 3
239000000556 agonist Substances 0.000 abstract 3
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical compound C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 abstract 3
239000003163 gonadal steroid hormone Substances 0.000 abstract 2
239000005556 hormone Substances 0.000 abstract 2
229940088597 hormone Drugs 0.000 abstract 2
206010028980 Neoplasm Diseases 0.000 abstract 1
230000002280 anti-androgenic effect Effects 0.000 abstract 1
239000000051 antiandrogen Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
238000002681 cryosurgery Methods 0.000 abstract 1
230000001419 dependent effect Effects 0.000 abstract 1
238000009472 formulation Methods 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
238000001959 radiotherapy Methods 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/36—Antigestagens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Diabetes (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)

AT96942812T 1995-12-15 1996-11-25 Behandlung von prostatakrebs mit lhrh- antagonisten ATE275962T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US08/573,109 US5780435A (en)	1995-12-15	1995-12-15	Methods for treating prostate cancer with LHRH-R antagonists
PCT/US1996/018911 WO1997022357A1 (en)	1995-12-15	1996-11-25	Methods for treating prostate cancer with lhrh antagonists

Publications (1)

Publication Number	Publication Date
ATE275962T1 true ATE275962T1 (de)	2004-10-15

Family

ID=24290700

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT96942812T ATE275962T1 (de)	1995-12-15	1996-11-25	Behandlung von prostatakrebs mit lhrh- antagonisten

Country Status (11)

Country	Link
US (6)	US5780435A (de)
EP (2)	EP0871468B1 (de)
JP (2)	JP4126094B2 (de)
AT (1)	ATE275962T1 (de)
AU (1)	AU730948B2 (de)
CA (1)	CA2238993C (de)
DE (1)	DE69633405T2 (de)
DK (1)	DK0871468T3 (de)
ES (1)	ES2227622T3 (de)
PT (1)	PT871468E (de)
WO (1)	WO1997022357A1 (de)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
US5691314A (en)	1996-03-18	1997-11-25	The Medical College Of Hampton Roads	Adjunctive therapy
US5968895A (en)	1996-12-11	1999-10-19	Praecis Pharmaceuticals, Inc.	Pharmaceutical formulations for sustained drug delivery
US6217844B1 (en)	1998-04-27	2001-04-17	Praecis Pharmaceuticals, Inc.	Methods for detecting lesions in dense breast tissue using LHRH antagonists
KR20010080007A (ko) *	1998-10-08	2001-08-22	다케다 야쿠힌 고교 가부시키가이샤	호르몬 의존성 암의 호르몬 비의존성 암으로의 변화 지연제
US6498181B1 (en) *	1999-01-06	2002-12-24	Maxim Pharmaceuticals	Synergistic tumorcidal response induced by histamine
US7361680B2 (en) *	1999-07-23	2008-04-22	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7151100B1 (en)	1999-07-23	2006-12-19	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7129262B2 (en) *	1999-07-23	2006-10-31	The Regents Of The University Of California	Indole compounds useful for the treatment of cancer
US7105560B1 (en)	1999-07-23	2006-09-12	The Regents Of The University Of California	Use of etodolac in the treatment of multiple myeloma
US6545034B1 (en) *	1999-07-23	2003-04-08	The Regents Of The University Of California	Use of etodolac for the treatment of chronic lymphocytic leukemia
US6428785B1 (en)	1999-10-28	2002-08-06	Immunolytics Inc.	Method and composition for treating prostate cancer
US7109171B2 (en) *	2000-02-28	2006-09-19	Praecis Pharmaceuticals Inc.	Methods for treating FSH related conditions with GnRH antagonists
WO2002002144A1 (fr) *	2000-07-05	2002-01-10	Takeda Chemical Industries, Ltd.	Preparations medicinales pour le traitement des maladies dependant des hormones sexuelles
JP2002080397A (ja) *	2000-07-05	2002-03-19	Takeda Chem Ind Ltd	性ホルモン依存性疾患の治療用医薬製剤
US20040152672A1 (en) *	2000-08-09	2004-08-05	Carson Dennis A.	Indole compounds useful for the treatment of cancer
WO2002056903A2 (en) *	2001-01-17	2002-07-25	Praecis Pharmaceuticals Inc.	Methods for treating hormone associated conditions using a combination of lhrh antagonists and specific estrogen receptor modulators
WO2003000156A1 (en) *	2001-06-22	2003-01-03	Southern Biosystems, Inc.	Zero-order prolonged release coaxial implants
US20060287282A1 (en) *	2001-06-25	2006-12-21	Steiner Mitchell S	Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
EP1429755A4 (de) *	2001-07-27	2004-08-11	Univ Rochester	Verwendung von vitamin-e-succinat und antiandrogen-kombination
DE10137174A1 (de) *	2001-07-31	2003-02-13	Zentaris Ag	Verwendung von LHRH-Antagonisten in nichtkastrierenden Dosen zur Verbesserung der T-Zellen-vermittelten Immunität
US20040138138A1 (en) *	2001-08-02	2004-07-15	Jurgen Engel	Use of LHRH-antagonists in doses that do not cause castration for the improvement of T-cell mediated immunity
US6844014B1 (en)	2002-07-22	2005-01-18	Stephen Rafkin	Herbal healing lotion for veterinary use
GB0219660D0 (en) *	2002-08-23	2002-10-02	Astrazeneca Ab	Therapeutic use
US7211599B2 (en) *	2002-09-19	2007-05-01	The Regents Of The University Of California	Use of etodolac to treat hyperplasia
GB0223367D0 (en) *	2002-10-09	2002-11-13	Astrazeneca Ab	Therapeutic treatment
GB0223854D0 (en) *	2002-10-12	2002-11-20	Astrazeneca Ab	Therapeutic treatment
AU2003300351A1 (en) *	2002-12-19	2004-07-14	Praecis Pharmaceuticals, Inc.	Methods of enhancing immune system function in a subject
WO2004087190A1 (en) *	2003-04-02	2004-10-14	Genix Therapeutics Inc.	Method for the treatment of prostate cancer
EP1620060B1 (de)	2003-04-29	2010-03-24	The General Hospital Corporation	Verfahren und vorrichtungen für die verzögerte freisetzung von mehreren arzneimitteln
GB0320806D0 (en) *	2003-09-05	2003-10-08	Astrazeneca Ab	Therapeutic treatment
GB0403744D0 (en) *	2004-02-20	2004-03-24	Astrazeneca Ab	Chemical process
GB0425854D0 (en) *	2004-11-25	2004-12-29	Astrazeneca Ab	Therapeutic treatment
US7918795B2 (en)	2005-02-02	2011-04-05	Gynesonics, Inc.	Method and device for uterine fibroid treatment
US7942867B2 (en) *	2005-11-09	2011-05-17	The Invention Science Fund I, Llc	Remotely controlled substance delivery device
US7815571B2 (en) *	2006-04-20	2010-10-19	Gynesonics, Inc.	Rigid delivery systems having inclined ultrasound and needle
US10058342B2 (en)	2006-01-12	2018-08-28	Gynesonics, Inc.	Devices and methods for treatment of tissue
US7874986B2 (en) *	2006-04-20	2011-01-25	Gynesonics, Inc.	Methods and devices for visualization and ablation of tissue
US11259825B2 (en)	2006-01-12	2022-03-01	Gynesonics, Inc.	Devices and methods for treatment of tissue
US20070161905A1 (en) *	2006-01-12	2007-07-12	Gynesonics, Inc.	Intrauterine ultrasound and method for use
US9357977B2 (en)	2006-01-12	2016-06-07	Gynesonics, Inc.	Interventional deployment and imaging system
US8206300B2 (en)	2008-08-26	2012-06-26	Gynesonics, Inc.	Ablation device with articulated imaging transducer
US20100056926A1 (en) *	2008-08-26	2010-03-04	Gynesonics, Inc.	Ablation device with articulated imaging transducer
US10595819B2 (en)	2006-04-20	2020-03-24	Gynesonics, Inc.	Ablation device with articulated imaging transducer
CA2680737C (en) *	2007-03-21	2015-12-15	Emisphere Technologies, Inc.	Allyloxy and alkyloxy benzoic acid delivery agents
CA2693735A1 (en) *	2007-07-13	2009-01-22	Yigal Gat	Diagnosis and treatment of varicocele and prostate disorders
US20100204639A1 (en) *	2007-07-13	2010-08-12	Yigal Gat	Diagnosis and treatment of varicocele and prostate disorders
US20090018486A1 (en) *	2007-07-13	2009-01-15	Menachem Goren	Diagnosis and treatment of vericocele and prostate disorders
US8088072B2 (en)	2007-10-12	2012-01-03	Gynesonics, Inc.	Methods and systems for controlled deployment of needles in tissue
US20090287081A1 (en) *	2008-04-29	2009-11-19	Gynesonics , Inc	Submucosal fibroid ablation for the treatment of menorrhagia
US8262574B2 (en)	2009-02-27	2012-09-11	Gynesonics, Inc.	Needle and tine deployment mechanism
TWI664425B (zh) *	2012-03-18	2019-07-01	日商資生堂股份有限公司	疾病樣本分析裝置、分析系統及分析方法
SG10201902568YA (en)	2012-09-26	2019-04-29	Aragon Pharmaceuticals Inc	Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
CN107778354B (zh) *	2016-08-25	2021-03-02	成都圣诺生物制药有限公司	一种合成阿巴瑞克的方法
AU2017359338B2 (en)	2016-11-11	2022-09-08	Gynesonics, Inc.	Controlled treatment of tissue and dynamic interaction with, and comparison of, tissue and/or treatment data
JP7184775B2 (ja)	2016-12-14	2022-12-06	パーデュー・リサーチ・ファウンデイション	黄体化ホルモン放出ホルモン受容体（ｌｈｒｈ－ｒ）コンジュゲートおよびその使用
WO2019078920A1 (en)	2017-10-16	2019-04-25	Aragon Pharmaceuticals, Inc.	ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC RESISTANT PROSTATE CANCER

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4666885A (en) *	1985-02-08	1987-05-19	Fernand Labrie	Combination therapy for treatment of female breast cancer
US4775660A (en) *	1984-08-02	1988-10-04	Fernand Labrie	Treatment of breast cancer by combination therapy
US5023234A (en) *	1985-02-08	1991-06-11	Fernand Labrie	Combination male breast cancer therapy
US4659695A (en) *	1985-02-08	1987-04-21	Fernand Labrie	Method of treatment of prostate cancer
US4760053A (en) *	1984-08-02	1988-07-26	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
US5064813A (en) *	1984-08-02	1991-11-12	Fernand Labrie	Combination therapy for selected sex steroid dependent cancers
US5110904A (en) *	1989-08-07	1992-05-05	Abbott Laboratories	Lhrh analogs
US5116615A (en) *	1989-01-27	1992-05-26	Immunolytics, Inc.	Method for treating benign prostatic hypertrophy
US5372996A (en) *	1989-03-10	1994-12-13	Endorecherche, Inc.	Method of treatment of androgen-related diseases
WO1991000731A1 (en) *	1989-07-07	1991-01-24	Endorecherche Inc.	Combination therapy for prophylaxis and/or treatment of benign prostatic hyperplasia
US5130137A (en) *	1989-08-09	1992-07-14	The General Hospital Corporation	Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for use in treating benign ovarian secretory disorders
US5180711A (en) *	1990-06-14	1993-01-19	Applied Research Systems Ars Holding N.V.	Combined treatment with gnrh antagonist and gnrh to control gonadotropin levels in mammals
US5413990A (en) *	1993-08-06	1995-05-09	Tap Pharmaceuticals Inc.	N-terminus modified analogs of LHRH
US5681817A (en) *	1994-02-04	1997-10-28	The Medical College Of Hampton Roads	Treatment of ovarian estrogen dependent conditions
US5677184A (en) *	1994-04-19	1997-10-14	Takeda Chemical Industries, Ltd.	CHO cells that express human LH-RH receptor
US5843901A (en) *	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
US5780435A (en) *	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
US5691314A (en)	1996-03-18	1997-11-25	The Medical College Of Hampton Roads	Adjunctive therapy

1995
- 1995-12-15 US US08/573,109 patent/US5780435A/en not_active Expired - Fee Related
1996
- 1996-11-25 ES ES96942812T patent/ES2227622T3/es not_active Expired - Lifetime
- 1996-11-25 EP EP96942812A patent/EP0871468B1/de not_active Expired - Lifetime
- 1996-11-25 AT AT96942812T patent/ATE275962T1/de not_active IP Right Cessation
- 1996-11-25 CA CA002238993A patent/CA2238993C/en not_active Expired - Fee Related
- 1996-11-25 AU AU11413/97A patent/AU730948B2/en not_active Ceased
- 1996-11-25 DK DK96942812T patent/DK0871468T3/da active
- 1996-11-25 US US08/755,593 patent/US5843902A/en not_active Expired - Fee Related
- 1996-11-25 JP JP52281397A patent/JP4126094B2/ja not_active Expired - Fee Related
- 1996-11-25 PT PT96942812T patent/PT871468E/pt unknown
- 1996-11-25 DE DE69633405T patent/DE69633405T2/de not_active Expired - Fee Related
- 1996-11-25 WO PCT/US1996/018911 patent/WO1997022357A1/en not_active Ceased
- 1996-11-25 EP EP02078871A patent/EP1297840A3/de not_active Withdrawn
1998
- 1998-07-01 US US09/108,664 patent/US6153586A/en not_active Expired - Lifetime
1999
- 1999-11-11 US US09/438,174 patent/US6180609B1/en not_active Expired - Lifetime
- 1999-11-11 US US09/438,718 patent/US6211153B1/en not_active Expired - Fee Related
2000
- 2000-10-26 US US09/697,409 patent/US6384017B1/en not_active Expired - Fee Related
2005
- 2005-09-29 JP JP2005285674A patent/JP2006022118A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0871468B1 (de)	2004-09-15
US6153586A (en)	2000-11-28
US6180609B1 (en)	2001-01-30
ES2227622T3 (es)	2005-04-01
DE69633405D1 (de)	2004-10-21
US5843902A (en)	1998-12-01
CA2238993A1 (en)	1997-06-26
HK1016087A1 (en)	1999-10-29
EP0871468A1 (de)	1998-10-21
AU730948B2 (en)	2001-03-22
EP1297840A3 (de)	2003-09-10
EP1297840A2 (de)	2003-04-02
JP2006022118A (ja)	2006-01-26
US6384017B1 (en)	2002-05-07
AU1141397A (en)	1997-07-14
PT871468E (pt)	2005-02-28
DK0871468T3 (da)	2005-01-24
JP4126094B2 (ja)	2008-07-30
US6211153B1 (en)	2001-04-03
US5780435A (en)	1998-07-14
DE69633405T2 (de)	2005-11-17
CA2238993C (en)	2004-10-12
JP2000513326A (ja)	2000-10-10
WO1997022357A1 (en)	1997-06-26

Legal Events

Date

Code

Title

Description

2005-08-15

UEP

Publication of translation of european patent specification

Ref document number: 0871468

Country of ref document: EP

2010-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE275962T1 (de)	2004-10-15	Behandlung von prostatakrebs mit lhrh- antagonisten
Lanoue et al.	2016	Basal cell carcinoma: a comprehensive review of existing and emerging nonsurgical therapies
HU902847D0 (en)	1991-11-28	Medical preparation and process for treating diseases linked with estrogenical sensitiveness
NZ285159A (en)	2000-10-27	Treatment of benign prostatic hyperplasia, endometriosis, prostatic carcinoma and obesity by administration of droloxifene
ATE177949T1 (de)	1999-04-15	Kombinationstherapie zur prophylaxe und/oder behandlung benigner prostatahyperplasie
DK0595796T3 (da)	2003-05-05	Fremgangsmåde til behandling af androgen-relaterede sygdomme
BR0113447A (pt)	2003-07-08	Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR9908592A (pt)	2001-04-24	Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit
ATE501722T1 (de)	2011-04-15	Therapeutische behandlung androgenrezeptorbedingter leiden
DE60026538D1 (de)	2006-05-04	Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
NO20071426L (no)	2007-06-18	Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib
DE69426334D1 (de)	2000-12-28	Parenterales Busulfan zur Behandlung von malignen Krankheiten
EP1348466A3 (de)	2003-10-29	Schmerzbehandlung mit Adenosin-Tetraphosphaten
NO20066054L (no)	2007-01-25	behandling med cisplatin og en EGFR-inhibitor
WO2000040229A3 (en)	2001-07-19	Synergistic tumorcidal response induced by histamine
CA2156481A1 (en)	1994-09-01	5-ht2 receptor antagonist compositions useful in treating venous conditions
NZ504928A (en)	2004-12-24	Combination of benzocycloheptapyridine compounds and antineoplastic drugs for treating proliferative diseases
WO2000061141A3 (en)	2001-03-01	Methods and compositions for enhancing delivery of therapeutic agents to tissues
WO2023077090A8 (en)	2023-06-01	Lag-3 antagonist therapy for hematological cancer
ID26965A (id)	2001-02-22	Obat untuk mencegah dan/atau mengobati kanker payudara, yang mengandung inhibitor aromatase steroid
WO2004056971A3 (en)	2005-03-10	Methods of treatment of a bcl-2 disorder using bcl-2 antisense oligomers
Zaccheo et al.	1998	Effect of early treatment of prostate cancer with the 5α‐reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats
WO2003039466A3 (en)	2004-01-15	Method of treating estrogen responsive breast cancer
DE69430356D1 (de)	2002-05-16	Karzinostatisches Mittel für Hormontherapie, das Dienogest als wirksamer Bestandteil enthält
BR9607178A (pt)	2004-10-19	Antagonista de peptìdeo de hormÈnio estimulando alfa -melanócitos, processos para a inibição da atividade de hormÈnio estimulando alfa-melanócitos em um tecido ou célula que responde a hormÈnio estimulando alfa -melanócitos, para o clareamento da complexação de um animal e para o tratamento de melanoma maligno, composição farmacêutica, e, kit